Redeye retains its positive view of Transtema, despite a soft Q3 report, which shows further declines in Norway, while Swedish profitability remains on the soft side. Although we cut our forecasts and Base Case, we still expect improving margins in 2026.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/